Pharmaceutical Regulatory Environment in India

The pharmaceutical regulatory environment in India is governed by a combination of central and state-level authorities and applicable legislation. The Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services, Ministry of Health and Family Welfare, performs important central regulatory functions relating to new drugs, clinical trials, imported drugs and other regulated products.

The regulatory framework operates through the Drugs and Cosmetics Act and Rules, the New Drugs and Clinical Trials Rules, 2019 (NDCTR 2019), and other applicable requirements.

Central Drugs Standard Control Organisation

CDSCO is India’s national regulatory authority for drugs and performs regulatory functions in coordination with State Drug Control Authorities.

Its responsibilities include areas such as:

• New drug approvals
• Clinical trial permissions
• Investigational new drugs
• Import of regulated drugs
• Certain licensing and regulatory activities
• Regulatory inspections
• Safety-related regulatory actions
• Coordination with state authorities

The Drugs Controller General (India), or DCG(I), performs important functions within the central regulatory system.

New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019 provide the principal current framework for the regulation of new drugs, investigational new drugs, clinical trials, bioavailability and bioequivalence studies, and related ethics committee requirements.

NDCTR 2019 replaced several older processes previously addressed primarily through the Drugs and Cosmetics Rules and Schedule Y.

The Rules establish requirements for applications, permissions, ethics committees, clinical trial conduct, safety reporting and other aspects of new-drug development.

Current rules, notices and regulatory information relating to new drugs and clinical trials are available from the Central Drugs Standard Control Organisation (CDSCO).

For additional background on the evolution of India’s clinical-trial regulations, see Indian Clinical Trial and Safety Regulations: From Schedule Y to NDCTR 2019.

Clinical Trial Applications

Clinical trials involving new or investigational drugs generally require appropriate permission from the Central Licencing Authority under NDCTR 2019.

Applications are submitted using the applicable forms and supporting documentation.

For example, Form CT-04 is used for an application for permission to conduct a clinical trial of a new drug or investigational new drug, with permission granted in Form CT-06 when applicable.

Clinical trial applications and related regulatory submissions are handled electronically through CDSCO’s SUGAM system where applicable.

Ethics Committees

Clinical trials must undergo appropriate ethical review.

Ethics committees reviewing clinical trials, bioavailability or bioequivalence studies covered by NDCTR 2019 are subject to applicable registration and regulatory requirements.

Ethics committees have an important role in protecting the rights, safety and well-being of trial participants and reviewing relevant clinical trial documents and information.

Regulatory permission and ethics committee review are separate but complementary requirements within the clinical research framework.

New Drug Approval

New drugs intended for import, manufacture or marketing in India are evaluated under the applicable provisions of NDCTR 2019 and related legislation.

The required development and regulatory pathway depends on factors such as the type of product, its approval status in other countries, available clinical evidence and the proposed indication or use.

CDSCO evaluates relevant quality, nonclinical and clinical information before granting applicable permissions.

India therefore has its own regulatory application and permission framework and should not be described simply as following the U.S. IND/NDA system.

Indian Pharmacopoeia Commission

The Indian Pharmacopoeia Commission (IPC), an autonomous institution under the Ministry of Health and Family Welfare, develops and publishes the Indian Pharmacopoeia.

The Indian Pharmacopoeia establishes official standards relating to the identity, purity and quality of medicines covered by the pharmacopoeia.

IPC also plays an important role in national pharmacovigilance activities.

Good Manufacturing Practice

Pharmaceutical manufacturing is subject to applicable Good Manufacturing Practice requirements under India’s drugs regulatory framework.

GMP requirements support consistent manufacture and control of medicinal products according to appropriate quality standards.

Regulatory oversight may involve central and state authorities depending on the product, licence and regulatory activity.

Manufacturers should maintain appropriate pharmaceutical quality systems, documentation, facilities, equipment, personnel, production controls and quality-control processes.

Pharmacovigilance Programme of India

The Pharmacovigilance Programme of India (PvPI) is the Government of India’s national programme for monitoring the safety of medicines.

The Indian Pharmacopoeia Commission functions as the National Coordination Centre for PvPI.

PvPI collects, collates and analyses suspected adverse drug reaction information and provides relevant recommendations to CDSCO for regulatory consideration.

Post-marketing pharmacovigilance requirements also apply to pharmaceutical companies according to applicable regulatory requirements.

Safety Reporting in Clinical Trials

Clinical trial safety reporting is governed by NDCTR 2019 and other applicable requirements.

Investigators and sponsors have defined responsibilities for identifying, documenting, assessing and reporting serious adverse events and other relevant safety information.

Safety reporting requirements during clinical development should be distinguished from routine post-marketing pharmacovigilance activities.

Drug Pricing

Pharmaceutical regulation and drug pricing are related but distinct areas.

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, is responsible for implementing applicable drug-pricing policies and monitoring regulated medicine prices.

Price control requirements are particularly relevant to medicines covered by applicable pricing orders and the National List of Essential Medicines.

Advertising and Promotion

Advertising and promotion of medicines in India are subject to applicable laws and regulatory requirements.

Relevant legislation includes the Drugs and Magic Remedies (Objectionable Advertisements) Act and associated rules, along with other requirements applicable to pharmaceutical promotion and claims.

Promotional communications should not make prohibited, misleading or unsupported claims.

Import of Pharmaceutical Products

Import of pharmaceutical products into India is subject to applicable licensing, registration and regulatory requirements.

CDSCO performs important central regulatory functions relating to imported drugs.

Requirements vary depending on the product and its regulatory status, and appropriate permissions should be obtained before regulated products are imported or marketed.

Intellectual Property

Pharmaceutical intellectual-property protection operates under India’s intellectual-property legislation and is separate from CDSCO’s assessment of pharmaceutical safety, efficacy and quality.

Patent matters are administered through India’s patent system rather than through CDSCO.

Regulatory approval of a medicine and patent protection are therefore separate legal and regulatory processes.

Central and State Regulatory Responsibilities

India’s pharmaceutical regulatory system involves both central and state authorities.

CDSCO performs specified central functions, while State Drug Control Authorities have important responsibilities relating to licensing, inspections, manufacturing and distribution under applicable legislation.

The exact regulatory authority involved depends on the product and activity being regulated.

Importance of the Pharmaceutical Regulatory Environment in India

The pharmaceutical regulatory environment in India covers clinical development, new-drug approval, manufacturing quality, pharmacovigilance, imports and other activities throughout the medicinal-product lifecycle.

Understanding NDCTR 2019, CDSCO and DCG(I) responsibilities, ethics committee requirements, state regulatory functions and the SUGAM submission system is particularly important for organizations developing or marketing pharmaceutical products in India.

The regulatory framework continues to evolve through amendments, guidance, notices and regulatory clarifications, making current official CDSCO requirements an important reference for regulatory planning and compliance.

You may be interested in the programs below: